Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
1.100
-0.185 (-14.40%)
At close: Nov 20, 2024, 4:00 PM
1.160
+0.060 (5.45%)
Pre-market: Nov 21, 2024, 7:40 AM EST
Genprex Employees
Genprex had 26 employees as of December 31, 2023. The number of employees decreased by 2 or -7.14% compared to the previous year.
Employees
26
Change (1Y)
-2
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$873,460
Market Cap
3.96M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Check-Cap | 85 |
Kindly MD | 65 |
Sharps Technology | 57 |
Applied DNA Sciences | 55 |
Sunshine Biopharma | 44 |
Aptevo Therapeutics | 40 |
Purple Biotech | 20 |
Galmed Pharmaceuticals | 8 |
GNPX News
- 23 hours ago - Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer - PRNewsWire
- 15 days ago - Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - PRNewsWire
- 21 days ago - Genprex to Participate in 2024 BIO Europe Conference - PRNewsWire
- 24 days ago - Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma - PRNewsWire
- 4 weeks ago - Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive - PRNewsWire
- 5 weeks ago - Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer - PRNewsWire
- 6 weeks ago - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - PRNewsWire
- 6 weeks ago - Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - PRNewsWire